Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Surrozen (Nasdaq: SRZN) has announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration on retinal diseases. Boehringer is advancing the development of SZN-413, a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wnt signaling, designed using Surrozen's SWAP™ technology.
SZN-413 offers the potential to restore retinal function in patients with retinal vascular diseases, which affect nearly 150 million people globally. Preclinical data suggest that SZN-413 could stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.
Craig Parker, President and CEO of Surrozen, expressed excitement about Boehringer's decision to proceed with SZN-413's development, highlighting the strong evidence supporting Fzd-4 specific Wnt signaling's role in retinal vasculature.
Surrozen (Nasdaq: SRZN) ha annunciato un pagamento di milestone di 10 milioni di dollari da Boehringer Ingelheim nell'ambito della loro collaborazione sulle malattie retiniche. Boehringer sta avanzando nello sviluppo di SZN-413, un anticorpo bispecifico che mira a inibire il segnale Wnt mediato dal recettore Frizzled Class 4 (Fzd4), progettato utilizzando la tecnologia SWAP™ di Surrozen.
SZN-413 offre il potenziale di ripristinare la funzione retinica in pazienti con malattie vascolari retiniche, che colpiscono quasi 150 milioni di persone in tutto il mondo. I dati preclinici suggeriscono che SZN-413 potrebbe stimolare il segnale Wnt nell'occhio, indurre una normale ricrescita dei vasi retinici, sopprimere la crescita patologica dei vasi e ridurre le perdite vascolari.
Craig Parker, Presidente e CEO di Surrozen, ha espresso entusiasmo riguardo alla decisione di Boehringer di proseguire con lo sviluppo di SZN-413, evidenziando le forti prove a supporto del ruolo del segnale Wnt specifico per Fzd-4 nella vascolarizzazione retinica.
Surrozen (Nasdaq: SRZN) ha anunciado un pago por hitos de 10 millones de dólares por parte de Boehringer Ingelheim como parte de su colaboración en enfermedades retinianas. Boehringer está avanzando en el desarrollo de SZN-413, un anticuerpo biespecífico que tiene como objetivo la señalización Wnt mediada por el receptor de clase Frizzled 4 (Fzd4), diseñado con la tecnología SWAP™ de Surrozen.
SZN-413 ofrece el potencial para restaurar la función retinal en pacientes con enfermedades vasculares retinianas, que afectan a casi 150 millones de personas en todo el mundo. Los datos preclínicos sugieren que SZN-413 podría estimular la señalización Wnt en el ojo, inducir la regeneración normal de los vasos retinianos, suprimir el crecimiento patológico de los vasos y reducir la fuga vascular.
Craig Parker, Presidente y CEO de Surrozen, expresó su entusiasmo por la decisión de Boehringer de continuar con el desarrollo de SZN-413, destacando las sólidas evidencias que respaldan el papel de la señalización Wnt específica para Fzd-4 en la vasculatura retiniana.
Surrozen (Nasdaq: SRZN)는 Boehringer Ingelheim로부터 1천만 달러의 마일스톤 지급을 발표하며 망막 질환에 대한 협력의 일환이라고 밝혔습니다. Boehringer는 Surrozen의 SWAP™ 기술을 사용하여 설계된 Fzd4에서 매개되는 Wnt 신호를 타겟으로 하는 SZN-413의 개발을 진행하고 있습니다.
SZN-413은 망막 혈관 질환이 있는 환자에서 망막 기능을 회복할 잠재력을 제공합니다. 이는 전 세계에서 거의 1억 5천만 명의 사람들에게 영향을 미칩니다. 전임상 데이터는 SZN-413이 눈에서 Wnt 신호를 자극하고, 정상적인 망막 혈관 재성장을 유도하며, 병리학적인 혈관 성장을 억제하고, 혈관 누수를 줄일 수 있음을 시사합니다.
Surrozen의 회장 겸 CEO인 Craig Parker는 Boehringer가 SZN-413의 개발을 진행하기로 한 결정에 대해 흥분을 표명하며 Fzd-4 특정 Wnt 신호가 망막 혈관에서 중요한 역할을 한다는 강력한 증거를 강조했습니다.
Surrozen (Nasdaq: SRZN) a annoncé un paiement d’étape de 10 millions de dollars de Boehringer Ingelheim dans le cadre de leur collaboration sur les maladies rétiniennes. Boehringer fait progresser le développement de SZN-413, un anticorps bispécifique visant la signalisation Wnt médiée par le récepteur Frizzled Class 4 (Fzd4), conçu grâce à la technologie SWAP™ de Surrozen.
SZN-413 offre le potentiel de restaurer la fonction rétinienne chez les patients atteints de maladies vasculaires rétiniennes, qui touchent près de 150 millions de personnes dans le monde. Les données précliniques suggèrent que SZN-413 pourrait stimuler la signalisation Wnt dans l'œil, induire une repousse normale des vaisseaux rétiniens, réprimer la croissance vasculaire pathologique et réduire les fuites vasculaires.
Craig Parker, Président et CEO de Surrozen, a exprimé son enthousiasme concernant la décision de Boehringer de poursuivre le développement de SZN-413, soulignant les solides preuves soutenant le rôle de la signalisation Wnt spécifique à Fzd-4 dans la vascularisation rétinienne.
Surrozen (Nasdaq: SRZN) hat eine Meilenstein-Zahlung von 10 Millionen US-Dollar von Boehringer Ingelheim im Rahmen ihrer Zusammenarbeit bei Netzhauterkrankungen angekündigt. Boehringer fördert die Entwicklung von SZN-413, einem bispezifischen Antikörper, der auf die Wnt-Signalübertragung über den Frizzled Class Receptor 4 (Fzd4) abzielt, und zwar unter Verwendung der SWAP™-Technologie von Surrozen.
SZN-413 bietet das Potenzial, die Netzhautfunktion wiederherzustellen bei Patienten mit Netzhautfaserkrankungen, die fast 150 Millionen Menschen weltweit betreffen. Präklinische Daten weisen darauf hin, dass SZN-413 die Wnt-Signalübertragung im Auge stimulieren, normales Wachstum der Netzhautfasern induzieren, pathologisches Wachstum der Fasern unterdrücken und die Gefäßleckage reduzieren könnte.
Craig Parker, Präsident und CEO von Surrozen, äußerte sich begeistert über die Entscheidung von Boehringer, mit der Entwicklung von SZN-413 fortzufahren, und hob die starken Beweise für die Rolle der Fzd-4 spezifischen Wnt-Signalübertragung in der Netzhautfaserung hervor.
- Earned $10 million milestone payment from Boehringer Ingelheim
- Boehringer Ingelheim advancing development of SZN-413 for potential clinical testing
- SZN-413 shows promise in preclinical data for treating retinal vascular diseases
- None.
Insights
The
The advancement of SZN-413 to prepare for potential clinical testing is a important step in the drug development process. It validates Surrozen's SWAP™ technology and their approach to targeting the Wnt pathway. However, investors should note that clinical testing is still ahead and success is not guaranteed.
The collaboration with Boehringer Ingelheim, a major pharmaceutical company, adds credibility to Surrozen's pipeline and may attract more investor attention. The large target market of 150 million people affected by retinal vascular diseases presents significant revenue potential if SZN-413 proves successful in future clinical trials.
While this news is positive, Surrozen remains a high-risk investment due to its early-stage pipeline and lack of approved products. The company's financial stability and future prospects will depend heavily on the continued progress of SZN-413 and other pipeline candidates.
The advancement of SZN-413 by Boehringer Ingelheim is a promising development in the field of retinal vascular diseases. The bi-specific antibody targeting Fzd4-mediated Wnt signaling represents an innovative approach to treating these conditions, which affect millions globally.
Preclinical data suggesting SZN-413's potential to stimulate normal retinal vessel regrowth, suppress pathological vessel growth and reduce vascular leakage is particularly intriguing. If these effects translate to humans, it could offer a significant therapeutic advantage over current treatments that primarily focus on managing symptoms rather than repairing damaged tissue.
However, it's important to temper enthusiasm with caution. The jump from preclinical to clinical studies is substantial and many promising compounds fail at this stage. The true potential of SZN-413 will only be revealed through rigorous clinical testing, which is yet to begin.
Nonetheless, the decision by Boehringer to advance the compound indicates confidence in its potential, which is a positive signal for both the scientific community and investors interested in novel approaches to treating retinal diseases.
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing
SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/Integrated (Wnt) signaling, designed using Surrozen’s SWAP™ technology
SZN-413 offers the possibility of restoring retinal function in patients living with retinal vascular diseases
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN) announced that Boehringer Ingelheim will further develop SZN-413 to advance the compound and prepare it for clinical testing. Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The milestone achievement triggers a
Retinal vascular diseases are responsible for a large proportion of global severe and moderate vision loss affecting close to 150 million people. Preclinical data have shown that SZN-413 could potentially stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth and reduce vascular leakage (CLICK HERE). It could potentially reverse the effects of retinal vascular diseases by repairing damaged tissue and restoring retinal function.
“We are excited that Boehringer has decided to move forward with the development of SZN-413 based on the completion of the initial period of joint research,” said Craig Parker, President and Chief Executive Officer of Surrozen. “With the strong genetic, experimental and clinical evidence of the role for Fzd-4 specific Wnt signaling in the retinal vasculature, we look forward to the further evaluation of this novel therapeutic approach to address one of the most urgent medical needs for people with retinal disease.”
About the Corporate Partnership
In the fourth quarter of 2022, Surrozen entered a strategic partnership with Boehringer Ingelheim for the research and development of SZN-413 for the treatment of retinal diseases. Under the terms of the agreement, Boehringer Ingelheim received an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases, in exchange for an upfront payment to Surrozen of
About Wnt Signaling
Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including liver, intestine, lung, kidney, retina, central nervous system, cochlea, bone, and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. Surrozen’s platform and proprietary technologies have the potential to overcome the limitations in pursuing the Wnt pathway as a therapeutic strategy.
About Surrozen
Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. For more information, please visit www.surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates SZN-043 and SZN-413 (including anticipated clinical development plans and timelines, the availability of data and such data supporting regulatory filings necessary for commencing clinical trials, the potential for such product candidates to be used to treat human disease, as well as the potential benefits of such product candidates), the Company’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales, the potential of Surrozen’s platform and proprietary technologies to overcome the limitations in pursuing the Wnt pathway as a therapeutic strategy, and the potential for the modulation of the Wnt signaling pathways to treat degenerative diseases and tissue injuries. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to SZN-043, SZN-413 and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for SZN-043, SZN-413, or other future product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2023 and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 as filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor and Media Contact:
Investorinfo@surrozen.com
FAQ
What milestone did Surrozen (SRZN) achieve in its retinal diseases collaboration?
What is SZN-413 and how does it work in treating retinal diseases?
How many people are affected by retinal vascular diseases according to Surrozen's (SRZN) press release?
What technology did Surrozen (SRZN) use to develop SZN-413?
